INTRODUCTION
The neurohypophysial nonapeptide hormone [arginine)]-vasopressin (AVP) has a diverse range of physiological effects, including contraction of vascular smooth muscle, antidiuresis, increased corticotropin release by the adenohypophysis, modulation of insulin secretion and regulation of testicular function. In addition, AVP-containing neurons project to sites other than the neural lobe and in these fibres AVP acts as a neurotransmitter\neuromodulator [1] . These various effects of AVP are mediated by specific vasopressin receptors expressed by target cells. Three different vasopressin receptors (VPRs), classified as V "a , V "b and V # , have been characterized pharmacologically [2, 3] . In addition, AVP is a high-affinity agonist at the oxytocin receptor (OTR). The V "a vasopressin receptor (V "a R), V "b vasopressin receptor (V "b R) and OTR stimulate phospholipase C but differ in the binding characteristics of certain AVP analogues, whereas V # vasopressin receptors (V # Rs) stimulate adenylate cyclase and display a fourth pharmacological profile [3] . The V "a R is widely distributed and mediates nearly all of the physiological actions of AVP, with the notable exceptions of antidiuresis (V # R) and corticotropin secretion (V "b R). All three VPRs [4] [5] [6] [7] [8] and the OTR [9] have been cloned and exhibit the characteristic motifs of G-protein-coupled receptors (GPCRs), including seven transmembrane domains [10] . Furthermore, sequence homology and related pharmacology establish these neurohypophysial hormone receptors as a subfamily of GPCRs.
Sequence analysis reveals that most GPCRs have at least one putative N-linked glycosylation site in their N-terminus based on Abbreviations used : AVP, [arginine 8 ]vasopressin ; GPCR, G-protein-coupled receptor ; OTR, oxytocin receptor ; PhAc, phenylacetyl ; VPR, vasopressin receptor ; V 1a R, V 1a vasopressin receptor ; rV 1a R, rat V 1a R; V 1b R, V 1b vasopressin receptor ; V 2 R, V 2 vasopressin receptor ; ACTH, adrenocorticotrophic hormone ; GnRH, gonadotropin-releasing hormone ; VIP-1, vasoactive intestinal peptide ; DMEM, Dulbecco's modified Eagle's medium ; NYT, acetyl-AsnTyr-Thr-amide. 1 To whom correspondence should be addressed (e-mail m.wheatley!bham.ac.uk).
HEK 293T cells. It was found that carbohydrate moieties are not required for the receptor to bind any of the four classes of ligand available, or for intracellular signalling. The glycosylation status of the V "a R did, however, regulate the level of total receptor expression and also the abundance of receptor at the cell surface. Furthermore, the nature of this regulation (increased or decreased expression) was dictated by the locus of the oligosaccharide modification. Modification of any one of the consensus sites alone, however, was sufficient for wild-type expression, indicating a redundancy within the glycosylation sites. A role for the carbohydrate in the correct folding or stabilization of the V "a R is indicated. Glycosylation is not required, however, for efficient trafficking of the receptor to the cell surface. This study establishes the functional importance of N-glycosylation of the V "a R.
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the Asn-Xaa-Ser\Thr consensus sequence [11] , although exceptions do occur. For example, the A #a -adenosine receptor only contains putative glycosylation sites on the second extracellular loop [12] , whereas the α #b -adrenergic receptor does not contain any putative sites at all [13] . For most GPCRs it has not been determined experimentally whether the putative sites are actually utilized. Interestingly, for some receptors where this has been ascertained, it has been shown that not all putative glycosylation sites are actually modified. For example, the gonadotropinreleasing hormone (GnRH) receptor contains putative glycosylation sites on its N-terminus and on its extracellular loops but only sites at the N-terminus are glycosylated [14] .
Studies into the function of glycosylation have been undertaken for relatively few GPCRs. Nevertheless, recent reports demonstrate that receptor glycosylation can be important for many aspects of receptor signalling, although the functional ramifications of glycosylation are not predictable from receptor to receptor. Consequently, glycosylation has been shown to be important in maintaining high-affinity binding and\or receptor coupling for rhodopsin [15] , β # -adrenergic receptor [16] , somatostatin receptor [17] and the gastrin-releasing peptide receptor (bombesin BB # ) [18] . In contrast, glycosylation of the receptors for vasoactive intestinal peptide (VIP-1) [19] , luteinizing hormone [20] , thyroid-stimulating hormone [21] , follicle-stimulating hormone [22] and GnRH [14] is important for receptor expression and\or stability.
In this report, we establish that three potential N-linked glycosylation sites in the V "a R are utilized and identify them. Furthermore, we show that the receptor is not O-glycosylated.
Disrupting the glycosylation sites by mutagenesis, individually and in combination, allowed us to probe the function of glycosylation at each locus and within each extracellular domain. Our results show that glycosylation is required for efficient folding of the receptor but it does not have a role in ligand recognition or G-protein coupling. It is noteworthy that the effect of glycosylation on V "a R expression was dependent on the locus, such that modification by carbohydrate was observed to increase expression, to decrease expression or to be neutral, depending on the asparaginyl residue(s) in question.
MATERIALS AND METHODS

Materials
Dulbecco's modified Eagle's medium (DMEM), glutamine, fetal bovine serum, sodium pyruvate and trypsin\EDTA (1i) were from Sigma (Poole, Dorset, U.K.) ; inositol-free DMEM, PBS and penicillin\streptomycin were from Gibco-BRL (Paisley, U.K.) ; cell-culture plasticware was from Costar (Cambridge, MA, U.S.A. 
Construction of glycosylation-mutant V 1a Rs
To disrupt N-glycosylation sites, individually and in combination, the Asn residue in each consensus sequon was mutated to Gln. Mutations were introduced in the rat V "a R (rV "a R) sequence by a PCR approach with specific sense and antisense oligonucleotides. Mutagenic sense oligonucleotides [incorporating the two base changes AAC CAG (in bold) for the required Asn Gln substitution (underlined)] were 5h-CC GTG GGC CAG TCC AGC CCG TG-3h, 5h-C GAG GGC TCC CAG GGC AGT CAG-3h and 5h-G GTG AAC CAG GGC ACT AAA ACC C-3h for the N14Q, N27Q and N198Q mutations respectively. For the N14Q and N27Q mutations, ApaI\BbuI-digested fragments were initially subcloned into pBluescript KSII (Stratagene) containing the V "a R sequence. For mammalian expression, the wild type, and N14Q and N27Q mutants were subcloned into the vector pcDNA3 (Invitrogen) using BamHI and EcoRI restriction sites. The N198Q mutant was introduced directly into the V "a R sequence in pcDNA3 utilizing unique SacII restriction sites.
For the [N14\27Q]V "a R double mutation, the N14Q mutant in the vector pcDNA3 was used as a template to incorporate the N27Q mutant by PCR. The PCR fragment (containing the N14Q and N27Q mutations) was subcloned into pcDNA3 using unique HindIII and Pfl23II restriction sites. In the case of the [N14\27\198Q]V "a R triple mutant, the SacII fragment (containing the N198Q mutation) was subcloned directly into pcDNA3 containing the [N14\27Q]V "a R double mutant. Verification of each construct was by automated sequencing (Alta Bioscience).
In vitro transcription and translation of V 1a Rs
Wild-type or mutant V "a Rs were subcloned into the unique BglII site in the transcription vector pSP64T [24] , utilizing unique BamHI restriction sites (generates cDNA fragments with compatible ends) flanking the V "a R cDNA sequence. Linearized pSP64T containing wild-type or mutant cDNA was used as a template to synthesize mRNA based on the protocol described previously [24] , using SP6 RNA polymerase for 60 min at 37 mC. Translation of mRNA was carried out using both a rabbit reticulocyte lysate system (supplied by Life Technologies) and a cell-free Xenopus egg extract (XE) system. Briefly, the reticulocyte lysate translation reactions were performed according to the supplier's instructions and contained 1 mCi of [$&S]methionine and 10 µg\ml mRNA. The Xenopus egg extract translation reactions were performed as described in [24] , containing 1 mCi\ml [$&S]methionine and 25 µg\ml mRNA in a final volume of 20 µl. After incubation at 21 mC for 1 h, Xenopus egg extract translations were diluted with 9 vol. of buffer [20 mM Tris\HCl, 50 mM KCl, 10 mM magnesium acetate, 100 mM NaCl and 10 % (w\v) glucose, pH 7.6] and the membrane and cytosol fractions separated by centrifugation at 12 000 g for 10 min at 4 mC. Samples were analysed by SDS\PAGE (10 % gels, w\v) followed by autoradiography.
Cell culture and transfection
HEK 293T cells were cultured routinely in DMEM supplemented with 10 % (v\v) fetal bovine serum, penicillin (100 i.u.\ml), streptomycin (100 µg\ml), glutamine (2 mM) and sodium pyruvate (1 mM). Cells were maintained in a humidified 5 % (v\v) CO # incubator at 37 mC. HEK 293T cells were seeded at a density of approx. 5i10& cells\100 mm dish, and transfected after 48 h using the calcium phosphate precipitation method. Briefly, a DNA\calcium phosphate co-precipitate, containing 10 µg of plasmid cDNA for each dish, was prepared 30 min before use. After incubation for 16 h, the media was replaced with growth media and cells incubated for 48 h before harvesting.
Radioligand-binding assays
Total V 1a R binding HEK 293T cell membranes were prepared to determine total receptor expression by radioligand-binding assays as described previously [25] . The protein concentration of membranes was determined using the Pierce BCA protein assay kit (Pierce Chemical Co.) with BSA as standard. Binding assays were essentially as described previously [26, 27] and contained membranes (50-300 µg), [Phe$-3,4,5-$H]AVP (0.3-1.1 nM) as tracer and competing ligand (at the concentration indicated) in a final volume of 0.5 ml. Non-specific binding was defined by unlabelled AVP (10 µM). After incubation for 90 min at 30 mC to establish equilibrium, bound and free ligand were separated by sedimentation at 12 000 g for 10 min. Membrane pellets were washed and solubilized using Soluene-350 (Packard) prior to liquid scintillation counting using HiSafe3 (Wallac) as cocktail.
Cell-surface V 1a R binding
Cell-surface expression was determined by whole-cell binding assays. Briefly, HEK 293T cells were seeded at a density of 1i10& cells\well in poly--lysine-coated 12-well plates and transfected after 24 h using Transfast4 (Promega). After 36 h, cells were washed twice with PBS, after which each well received 0.5 ml of binding buffer containing 2 % (w\v) BSA and
Plates were incubated for 90 min at 30 mC before removal of the medium by aspiration. After two rinses with ice-cold PBS, 0.5 ml of 0.1 M NaOH was added to each well to extract radioactivity. After 15 min of incubation at 37 mC, the medium from the plates was transferred to scintillation vials containing 10 ml of HiSafe3 scintillation cocktail.
Analysis of binding data
Radioligand-binding results are expressed as a percentage of the control (i.e. specific binding in the absence of the competing ligand). IC &! values were determined by non-linear regression after the fitting of Langmuir binding isotherms to experimentally determined data using the 
Measurement of AVP-induced accumulation of InsPs
HEK 293T cells were seeded at a density of 2.5i10& cells\well in poly--lysine-pre-treated six-well plates. AVP-induced accumulation of InsPs was assayed in transfected cells as described previously [29, 30] . Essentially, 24 h post-transfection, medium was replaced with serum-free, inositol-free, DMEM containing 2.5 µCi\ml 2-myo-[$H]inositol. After 48 h at 37 mC, cells were washed with PBS and incubated with medium containing 10 mM LiCl for 30 min, followed by the addition of AVP at the concentration indicated. Incubations were terminated by adding 0.5 ml of 5 % (v\v) perchloric acid containing 1 mM EDTA and 1 mg\ml phytic acid hydrosylate. Cells were pelleted at 12 000 g for 5 min, supernatants neutralized on ice with 1.2 M KOH, 10 mM EDTA and 50 mM Hepes, and samples loaded on to 0.8 ml Bio-Rad AG1-X8 columns (formate form). After elution of inositol (10 ml water) and glycerophosphoinositol (10 ml of 25 mM ammonium formate), a mixed InsP fraction containing inositol mono-, bis-, tris-and tetrakisphosphates was eluted (10 ml of 1.25 M ammonium formate containing 0.1 M formic acid). Radioactivity was determined using Ultima-Flo AF scintillant (Packard). EC &! values were determined by non-linear regression after fitting of logistic sigmoidal curves to experimental data.
RESULTS
Establishing the glycoprotein nature of the V 1a R
Examination of the sequences of the three VPR subtypes and the OTR, cloned from a range of species, reveals that they all possess putative glycosylation sites at their N-termini (Figure 1 ). V "a Rs cloned from rat, human and mouse contain four conserved consensus sequences for N-linked glycosylation [4, 31, 32] . Two sites are present on the N-terminus (Asn"% and Asn#( for rV "a R), and one site is present on each of the second and third extracellular loops (Asn"*) and Asn$$$ respectively in the rV "a R). For the OTR, three glycosylation sites are present on the Nterminus, whereas V "b R and V # R contain only one glycosylation site (Figure 1) . The V "a R is unique in this family in that it
Figure 1 Location of putative glycosylation sites on the VPR/OTR family of receptors
Putative glycosylation sites are indicated by branched chains.
possesses conserved glycosylation sites within the second and third extracellular loops. The rV # R has one additional consensus site in the second extracellular loop but this is not conserved in either the human or porcine V # Rs [5, 33] . The existence of a consensus sequence for N-glycosylation (Asn-Xaa-Ser\Thr) in an amino acid sequence does not necessarily result in a glycosylated protein. It was therefore important to establish experimentally which, if any, of the canonical sites of the V "a R are actually utilized by oligosaccharyltransferase. To this end, we employed a Xenopus egg extract in itro cell-free translation system, which has been shown to support appropriate N-linked, and O-linked, glycosylation [24, 34] .
To establish whether the V "a R is indeed glycosylated, V "a R mRNA was translated in itro using both a rabbit reticulocyte lysate translation system, which does not support glycosylation, and the Xenopus extract, which does. Inclusion of [$&S]methionine generated a labelled translation product that could be analysed by SDS\PAGE. Translation with the reticulocyte lysate system produced a single product with an apparent molecular mass of 35 kDa (Figure 2 ), corresponding to the non-glycosylated receptor. The 48 kDa band observed using this system with either water or V "a R mRNA is a well-characterized methionine-binding protein present in the lysate [35] . When V "a R mRNA was translated in the Xenopus extract, the product migrated with an apparent molecular mass of 46 kDa. The reduced mobility of the translation product generated in this extract compared with the reticulocyte lysate is entirely consistent with glycosylation of the V "a R. This was confirmed using the tripeptide acetyl-AsnTyr-Thr-amide (NYT), which corresponds to an N-glycosylation consensus site. Addition of NYT to the Xenopus extract completely suppressed V "a R glycosylation, resulting in a translation product that co-migrated with that from the reticulocyte lysate (Figure 2) . It was noteworthy that the V "a R was efficiently segregated into membranes as no receptor was detected in the supernatant from translation reactions (Figure 2) .
Figure 2 In vitro translation and glycosylation of the V 1a R
Translational products from the reticulocyte lysate after addition of water (RLO) or V 1a R mRNA (RLV) were analysed by SDS/PAGE (10 % gel, w/v). Translation products from Xenopus egg extract were separated by centrifugation to yield membrane and supernatant components. Membranes from translation reactions in the absence (XMk) or presence (XMj) of the tripeptide inhibitor NYT (1 mM) were analysed separately to the supernatant from the reactions without (XSk) or with (XSj) tripeptide. Molecular-mass markers are shown.
Figure 3 Determination of the number of V 1a R glycosylation sites utilized
Progressive inhibition of N-linked glycosylation was achieved by titrating increasing concentrations of the tripeptide NYT into the Xenopus egg extract system. Translation products of V 1a R mRNA were analysed by SDS/PAGE (10 % gel, w/v). The number of glycosylation sites utilized in each translation product is indicated. Molecular-mass markers are also shown.
Determination of the number of putative glycosylation sites actually utilized
To assess the number of putative N-linked glycosylation sites actually utilized, the receptor mRNA was translated using the Xenopus extract in the presence of increasing concentrations of the tripeptide NYT. Titration with NYT resulted in gradual inhibition of N-glycosylation to reveal four products, each representing a different glycosylation state of the V "a R ( Figure  3 ). Each product exhibited a different apparent mass, reflecting differences in the number of sites modified. Bands were observed at 35 kDa (non-glycosylated), 39 kDa (one glycosylation site utilized), 43 kDa (two sites utilized) and 46 kDa (three sites utilized). In each case, oligosaccharide modification resulted in reduced migration equivalent to an apparent molecular mass of 3-4 kDa. The V "a R, therefore, is modified at only three of the four putative N-linked glycosylation sites. As to the identity of the non-glycosylated site, it was reasoned that Asn$$$ in the third extracellular loop (Figure 1 ) was the most likely candidate. The glycosylation consensus site (Asn-Xaa-Ser\Thr) at this locus is Asn-Pro-Ser. The prolyl$$% at position Xaa can prevent such a sequence acting as a glycosyl acceptor [36] . Further support is provided by analysing sequence homology for the V "a R cloned from different species. Sheep V "a R has only three putative glycosylation sites, which correspond to Asn"%, Asn#( and Asn"*) of rV "a R [37] . An Asn is conserved within the third extracellular loop of the sheep receptor (corresponding to Asn$$$ in rat) ; however, an Ala replaces the necessary Ser\Thr of the consensus sequence, rendering this site non-functional.
In vitro translation of a non-glycosylated V 1a R
To verify that the three residues Asn"%, Asn#( and Asn"*) account for all the glycosylation sites of the V "a R, the construct [N14\ 27\198Q]V "a R was engineered, which would ablate any glycosylation at these sites. This non-glycosylated mutant construct was translated in both the Xenopus extract and reticulocyte lysate systems and the products compared with wild-type receptor. The [N14\27\198Q]V "a R translation product generated by the Xenopus extract was identical with that from the reticulocyte lysate preparation when analysed by SDS\PAGE, thereby establishing that the [N14\27\198Q]V "a R receptor protein was not glycosylated (Figure 4 , compare lanes 4 and 6). This conclusion was confirmed by the observation that the presence of the NYT peptide in the Xenopus extract had no effect on the apparent size of the [N14\27\198Q]V "a R receptor protein (Figure 4 , compare lanes 4 and 5). In marked contrast, when the wild-type receptor was translated in parallel, the Xenopus extract product migrated with a higher apparent mass than that of the reticulocyte lysate product. Furthermore, inclusion of the NYT peptide in the extract abolished this difference (Figure 4, lanes 1-3) . This is exactly what would be expected for an N-glycosylated protein.
The observation that the wild-type V "a R and the [N14\27\ 198Q]V "a R mutant generated products of the same apparent mass when translated in the Xenopus extract plus NYT, and also in the reticulocyte lysate, established that the residues Asn"%, Asn#( and Asn"*) accounted for all the glycosylation sites of the V "a R. In addition, this indicated that the V "a R is not O-glycosylated.
Pharmacological characterization of V 1a Rs with glycosylation ablated at a single site
To investigate whether glycosylation of individual asparaginyl residues had a role in V "a R function, a series of three mutant receptors was engineered in which each of the individual glycosylation sites was sequentially disrupted. Table 1 . In all cases, the binding affinities (K d ) exhibited were very similar to that of wild-type V "a R. The effect of disrupting glycosylation at a single site on intracellular signalling was also investigated. AVP-induced accumulation of InsPs was assayed and the dose-response curves are presented in Figure 5 . Disruption of any one of the three glycosylation sites did not perturb second-messenger generation.
Pharmacological characterization of V 1a Rs with glycosylation ablated in different domains
The use of peptide mimetics [38] , photoaffinity labelling [39] and mutagenesis [40, 41] have shown that AVP binding involves extracellular receptor epitopes. In addition, it was demonstrated earlier in this study that glycosylation of V "a R occurs on two discrete extracellular domains, the N-terminal domain and the second extracellular loop. Consequently, it was possible that oligosaccharide modification of these domains may influence ligand recognition by the receptor. The role of glycosylation of each of these extracellular segments was investigated. Three constructs were studied, one non-glycosylated at the N-terminus but glycosylated on the second extracellular loop ([N14\27Q]-V "a R), another non-glycosylated on the second extracellular loop but glycosylated at the N-terminus ([N198Q]V "a R) and a third non-glycosylated on both domains ([N14\27\198Q]V "a R). The results of radioligand-binding studies using the four different classes of ligand available are presented in Table 2 . Nonglycosylation of either the N-terminus or second extracellular loop did not markedly affect the pharmacological profile of the V "a R compared with the wild type. Furthermore, the fully nonglycosylated receptor ([N14\27\198Q]V "a R) exhibited wild-type pharmacology. The intracellular signalling of all of these glycosylation mutants was also unimpaired ( Figure 6 ).
The glycosylation status of the V 1a R regulates its expression
The expression of the receptors with differing glycosylation status was determined by radioligand-binding studies (Figure 7) . For each construct, the total receptor expression was calculated from experiments using a broken cell (membrane) preparation. Non-glycosylation of Asn"*) ([N198Q]V "a R) had no effect on total receptor expression (76p17 %, n l 3, compared with the wild type). In contrast, disruption of either one of the two glycosylation sites located in the N-terminus resulted in an approx. 3-fold increase in total receptor expression, with [N14Q]-V "a R and [N27Q]V "a R being expressed at 277p42 % (n l 3) and 266p89 % (n l 3) respectively compared with the wild type ( Figure 7A , white bars). Deletion of both of these sites simultaneously in the [N14\27Q]V "a R construct, however, produced wild-type expression levels (116p9 %, n l 3 ; Figure 7A , white bars). In contrast, the fully non-glycosylated receptor [N14\27\ 198Q]V "a R had severely impaired expression, being only 27p9 % of the wild-type total expression ( Figure 7A, white bars) . The role of glycosylation in receptor expression was investigated further by using whole-cell radioligand-binding studies to quantify only those receptors that were efficiently trafficked to the cell surface ( Figure 7A, black bars) . It was apparent from these studies that the cell-surface expression of the constructs did not parallel the total receptor expression. Consequently, disruption of a single glycosylation site located in either the Nterminus ([N14Q]V "a R or [N27Q]V "a R) or in the extracellular loop ([N198Q]V "a R) had no significant effect on the number of receptors expressed on the surface of the cell compared with the wild type ( Figure 7A, black bars) . A lack of N-terminal glycosylation in the [N14\27Q]V "a R mutant resulted in increased expression at the cell surface (177p10 %, n l 3, compared with the wild type), whereas the totally non-glycosylated receptor ([N14\27\198Q]V "a R) was expressed poorly on the plasma membrane (49p4 % of wild type, n l 3 ; Figure 7A , black bars).
In Figure 7 (B), the distribution of the receptor between the cell surface and the interior of the cell is presented for each of the receptor constructs. This distribution pattern varies from 90 % of the receptors being located in intracellular compartments for [N27Q]V "a R, to 80 % of the receptors being present in the plasma membrane for [N14\27\198Q]V "a R.
DISCUSSION
Analysis of the sequences of the GPCR family reveals that, with very few exceptions, they possess putative glycosylation sites at their N-termini, although the number and location of these sites varies. In addition, some receptors also have putative glycosylation sites within the extracellular-loop regions. This conservation of post-translational modification throughout the GPCR family is suggestive of a functional role. Unfortunately, for the vast majority of GPCRs, characterization of receptor glycosylation has not proceeded beyond identifying putative glycosylation sites in the amino acid sequence. This information is only of limited use, however, as not all consensus sites are actually utilized by the oligosaccharyltransferase in the endoplasmic reticulum.
In the present study we identified the glycosylation sites utilized in the V "a R using a combination of a rabbit reticulocyte lysate translation system (which does not support glycosylation) and a Xenopus egg extract cell-free translation system (which is glycosylation-competent [24, 34] ). Our data show that there are three residues modified by carbohydrate, Asn"% and Asn#( in the N-terminus and Asn"*) in the second extracellular loop. Asn$$$ located in the third extracellular loop constitutes part of an AsnXaa-Ser\Thr consensus site but is not modified, most probably because of the disruptive effect of the juxtaposed Pro$$% [36] . A recent survey of multi-span membrane glycoproteins revealed that glycosylation of more than one extracellular segment is very unusual [42] . Indeed to our knowledge, within the GPCR family, only the V "a R (this study), angiotensin AT " receptor [43] and the histamine H # receptor [44] have been shown to possess N-linked oligosaccharide on both the N-terminus and on an extracellular loop. Many GPCRs have consensus sites in these two segments but in most cases the sites have not been shown to be actually modified by carbohydrate. Of the few GPCRs for which glycosylation has been studied experimentally, rhodopsin, the VIP-1 receptor and the GnRH receptor all have consensus glycosylation sites on both the N-terminus and on an extracellular loop. However, rhodopsin has carbohydrate linked only at the Nterminus (Asn# and Asn"&) but not in the second extracellular loop (Asn#!!) [15] . Likewise, the VIP-1 receptor is glycosylated at the N-terminus (Asn&), Asn'* and Asn"!!) but not at the glycosylation consensus site in the third extracellular loop (Asn#*$) [19] . The GnRH receptor is glycosylated at the N-terminus (Asn% and Asn")) but not at Asn"!#, which is within a consensus site in the first extracellular loop [14] . However, the Asn"!# itself is a critical determinant for agonist potency [45] . The glycosylation site in the second extracellular loop of the V "a R (Asn"*) in the rat) is conserved in all species cloned to date. In addition, it is also conserved in the vasotocin receptor, which shares 61 % identity with the V "a R and at which AVP is an agonist [46] . We would therefore predict that Asn"'* of the vasotocin receptor (corresponding to Asn"*) of the rV "a R) is also glycosylated. Disruption of the three N-glycosylation sites of the V "a R by site-directed mutagenesis, or suppression of N-glycosylation by the NYT peptide, generated a translation product that was indistinguishable from the non-glycosylated receptor produced by the reticulocyte lysate system (Figure 4 ). These data establish that the V "a R is not O-glycosylated. To date the only GPCR reported to possess O-glycosylation is the V # R [47] . It has been well established by peptide mimetics [38] , mutagenesis [40, 41] and photoaffinity radiosequencing [39] that extracellular loops of VPRs have a role in ligand recognition. Furthermore, a subdomain of the N-terminus of the V "a R and OTR is critical for high-affinity agonist binding and signalling [48, 49] . Consequently, oligosaccharide side chains modifying the N-terminus and\or the second extracellular segment of the V "a R might influence the pharmacology of the receptor. Radioligandbinding assays and second-messenger assays of a series of glycosylation-defective V "a R constructs indicated that N-linked carbohydrate does not have a role in the receptor binding any of the four classes of ligand available (Tables 1 and 2 ) or in intracellular signalling (Figures 5 and 6 ).
Our data establish that the glycosylation status of the V "a R regulates the level of receptor expression. Furthermore, the nature of this regulation is dictated by the locus of the oligosaccharide modification within the receptor. Glycosylation of the receptor's N-terminus is not required for normal expression as the total expression of a non-glycosylated N-terminus construct ([N14\27Q]V "a R) was not significantly different from wild-type levels ( Figure 7A , white bars). This established that glycosylation of a single site in the second extracellular loop (Asn"*)) was sufficient for normal V "a R expression. However, glycosylation of Asn"*) was not a prerequisite for wild-type expression as this site could be ablated without detriment ( Figure 7A ). It seems, therefore, that there is a high degree of redundancy in utilizing three glycosylation sites distributed between two extracellular segments. An unexpected observation was that if the N-terminus of the receptor was glycosylated at only one site rather than two, total expression was increased 3-fold ( Figure 7A ). This contrasts with the mouse GnRH receptor, where deletion of either one of the two N-terminal glycosylation sites decreased expression [14] , and the human GnRH receptor, where expression was increased by engineering in a second glycosylation site [50] . At least one glycosylation site must be modified by oligosaccharide, however, for the receptor to exhibit wild-type expression, as the totally non-glycosylated V "a R ([N14\27\198Q]V "a R) was expressed at very low levels ( Figure 7A ). This contrasts markedly with the V # R, which is expressed normally when its single N-glycosylation site is disrupted [51] . However, it is perhaps relevant to note in this regard that, as cited earlier, the V # R is also O-glycosylated, unlike the V "a R [46] . The related OTR has three glycosylation sites in the N-terminus (Figure 1 ), which appear similar to the V "a R in that individually they do not seem to have a role in ligand binding or signalling [52] . It is not known whether glycosylation has a role in expression of the OTR, as the fully non-glycosylated OTR has not been studied.
In addition to assaying total receptor expression, we also assayed cell-surface expression of the various constructs using whole-cell binding. These studies revealed that there was not a direct correlation between the total level of expression and the abundance of receptor at the cell surface. Consequently, although total expression of [N14Q]V "a R and [N27Q]V "a R was approx. 3-fold higher than that of wild-type V "a R ( Figure 7A , white bars), there was no significant difference in the cell-surface expression of all these receptors ( Figure 7A, black bars) . Obviously, this means that a smaller percentage of the [N14Q]V "a R and [N27Q]-V "a R receptors synthesized by the cell were trafficked to the plasma membrane ( Figure 7B ). In contrast, total expression of the fully non-glycosylated receptor [N14\27\198Q]V "a R was markedly lower (27 %) than wild-type V "a R. However, the vast majority of these receptors were at the cell surface (80 %, Figure  7B ). This suggests that in the absence of modification by oligosaccharide, there is decreased production of functional receptor by the cell. Nevertheless, once assembled successfully, the non-glycosylated receptor is transported efficiently to the plasma membrane.
In conclusion, the V "a R is glycosylated at three positions, two in the N-terminus (Asn"% and Asn#() and one in the second extracellular loop (Asn"*)). Oligosaccharide must be linked to at least one of these loci for normal receptor expression but this modification by carbohydrate does not influence either ligand recognition or intracellular signalling. Glycosylation is required for the V "a R to be folded efficiently into the functional conformation, or stabilizes such a conformation. However, it is not a prerequisite for trafficking of the receptor to the cell surface.
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